Antibiotic resistance of pathogens causing community-acquired pneumonia

Seminars in Respiratory and Critical Care Medicine

Volumn 33, Issue 3, 2012, Pages 232-243

  Feldman, Charles ^a,b   Anderson, Ronald ^c,d  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND MEDICAL SCHOOL   (South Africa)

^c UNIVERSITY OF PRETORIA   (South Africa)

^d NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

Author keywords

lactam antibiotics; antibiotic resistance; biofilm formation; community acquired pneumonia; fluoroquinolones; macrolides; quorum sensing

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN; CLINDAMYCIN; ERYTHROMYCIN; FOSFOMYCIN; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; LINEZOLID; MACROLIDE; MESYLIC ACID ETHYL ESTER; METHYLNITROSOUREA; METICILLIN; MINOCYCLINE; NAPROXEN; PENICILLIN G; POLYPEPTIDE ANTIBIOTIC AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL SURVIVAL; BIOFILM; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; DISEASE EXACERBATION; DRUG CHOICE; DRUG TREATMENT FAILURE; GENETIC RESISTANCE; GRAM NEGATIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROORGANISM; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MYCOPLASMA PNEUMONIAE; NONHUMAN; PERITONITIS; PRACTICE GUIDELINE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; QUORUM SENSING; RESPIRATORY TRACT DISEASE; RISK FACTOR; SALMONELLA TYPHIMURIUM; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; BIOFILMS; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS; PNEUMONIA, BACTERIAL;

EID: 84862493012     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0032-1315635     Document Type: Article

References (123)

1. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax: 2012; 67 1 71 79
2. File TM Jr, Marrie TJ. Burden of community-acquired pneumonia in North American adults. Postgrad Med: 2010; 122 2 130 141
3. Isturiz RE, Luna CM, Ramirez J. Clinical and economic burden of pneumonia among adults in Latin America. Int J Infect Dis: 2010; 14 10 e852 e856
4. Song J-H, Thamlikitkul V, Hsueh P-R. Clinical and economic burden of community-acquired pneumonia amongst adults in the Asia-Pacific region. Int J Antimicrob Agents: 2011; 38 2 108 117
5. Ramirez JA, Anzueto AR. Changing needs of community-acquired pneumonia. J Antimicrob Chemother: 2011; 66 03 iii3 iii9
6. Huang SS, Johnson KM, Ray GT., et al. Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine: 2011; 29 18 3398 3412
7. Ewig S, Torres A. Community-acquired pneumonia as an emergency: time for an aggressive intervention to lower mortality. Eur Respir J: 2011; 38 2 253 260
8. Feikin DR, Feldman C, Schuchat A, Janoff EN. Global strategies to prevent bacterial pneumonia in adults with HIV disease. Lancet Infect Dis: 2004; 4 7 445 455 (Pubitemid 38844129)
9. Welte T, Köhnlein T. Global and local epidemiology of community-acquired pneumonia: the experience of the CAPNETZ Network. Semin Respir Crit Care Med: 2009; 30 2 127 135
10. Woodhead M. The European vision of community-acquired pneumonia. Semin Respir Crit Care Med: 2009; 30 2 136 145
11. Niederman MS. Community-acquired pneumonia: the U.S. perspective. Semin Respir Crit Care Med: 2009; 30 2 179 188
12. Jones RN, Jacobs MR, Sader HS. Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia. Int J Antimicrob Agents: 2010; 36 3 197 204
13. Polverino E, Torres Marti A. Community-acquired pneumonia. Minerva Anestesiol: 2011; 77 2 196 211
14. Metlay JP, Singer DE. Outcomes in lower respiratory tract infections and the impact of antimicrobial drug resistance. Clin Microbiol Infect: 2002; 8 02 1 11 (Pubitemid 35203497)
15. Jacobs MR, Anon J, Appelbaum PC. Mechanisms of resistance among respiratory tract pathogens. Clin Lab Med: 2004; 24 2 419 453 (Pubitemid 38737260)
16. Lynch JP III, Zhanel GG. Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. Curr Opin Pulm Med: 2010; 16 3 217 225
17. Feldman C. Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia. J Lab Clin Med: 2004; 143 5 269 283 (Pubitemid 38586492)
18. Lynch JP III, Zhanel GG. Streptococcus pneumoniae: does antimicrobial resistance matter? Semin Respir Crit Care Med: 2009; 30 2 210 238
19. Feldman C, Anderson R. Bacteraemic pneumococcal pneumonia: current therapeutic options. Drugs: 2011; 71 2 131 153
20. Felmingham D, Feldman C, Hryniewicz W., et al. Surveillance of resistance in bacteria causing community-acquired respiratory tract infections. Clin Microbiol Infect: 2002; 8 02 12 42 (Pubitemid 35203498)
21. Klugman KP, Low DE, Metlay J, Pechere J-C, Weiss K. Community-acquired pneumonia: new management strategies for evolving pathogens and antimicrobial susceptibilities. Int J Antimicrob Agents: 2004; 24 5 411 422 (Pubitemid 39425150)
22. Alpuche C, Garau J, Lim V. Global and local variations in antimicrobial susceptibilities and resistance development in the major respiratory pathogens. Int J Antimicrob Agents: 2007; 30 02 S135 S138
23. Goto H, Shimada K, Ikemoto H, Oguri T.; Study Group on Antimicrobial Susceptibility of Pathogens Isolated from Respiratory Infections. Antimicrobial susceptibility of pathogens isolated from more than 10,000 patients with infectious respiratory diseases: a 25-year longitudinal study. J Infect Chemother: 2009; 15 6 347 360
24. File TM Jr. The science of selecting antimicrobials for community-acquired pneumonia (CAP). J Manag Care Pharm: 2009; 15 2, Suppl S5 S11
25. Jacobs MR. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin Microbiol Infect: 2001; 7 11 589 596 (Pubitemid 34960355)
26. Garau J. Role of beta-lactam agents in the treatment of community-acquired pneumonia. Eur J Clin Microbiol Infect Dis: 2005; 24 2 83 99 (Pubitemid 40487376)
27. Owens RC Jr, Shorr AF. Rational dosing of antimicrobial agents: pharmacokinetic and pharmacodynamic strategies. Am J Health Syst Pharm: 2009; 66 12, Suppl 4 S23 S30
28. Van Bambeke F, Reinert RR, Appelbaum PC, Tulkens PM, Peetermans WE. Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options. Drugs: 2007; 67 16 2355 2382 (Pubitemid 350071047)
29. Jacobs MR. Antimicrobial-resistant Streptococcus pneumoniae: trends and management. Expert Rev Anti Infect Ther: 2008; 6 5 619 635
30. Song J-H, Chung DR. Respiratory infections due to drug-resistant bacteria. Infect Dis Clin North Am: 2010; 24 3 639 653
31. Feldman C, Brink AJ, von Gottberg A., et al. Antimicrobial susceptibility of pneumococcal isolates causing bacteraemic pneumococcal pneumonia: analysis using current breakpoints and fluoroquinolone pharmacodynamics. Int J Antimicrob Agents: 2010; 36 1 95 97
32. Yu VL, Chiou CC, Feldman C., et al. International Pneumococcal Study Group. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis: 2003; 37 2 230 237 (Pubitemid 36930354)
33. Amsden GW. Pneumococcal macrolide resistancemyth or reality? J Antimicrob Chemother: 1999; 44 1 1 6
34. Lonks JR, Garau J, Medeiros AA. Implications of antimicrobial resistance in the empirical treatment of community-acquired respiratory tract infections: the case of macrolides. J Antimicrob Chemother: 2002; 50 Suppl S2 87 92
35. Lynch JP III, Martinez FJ. Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia. Clin Infect Dis: 2002; 34 01 S27 S46 (Pubitemid 34155293)
36. Nuermberger E, Bishai WR. The clinical significance of macrolide-resistant Streptococcus pneumoniae: it's all relative. Clin Infect Dis: 2004; 38 1 99 103 (Pubitemid 38045880)
37. Fuller JD, McGeer A, Low DE. Drug-resistant pneumococcal pneumonia: clinical relevance and approach to management. Eur J Clin Microbiol Infect Dis: 2005; 24 12 780 788 (Pubitemid 43042784)
38. Pletz MW, van der Linden M, von Baum H, Duesberg CB, Klugman KP, Welte T.; CAPNETZ study group. Low prevalence of fluoroquinolone resistant strains and resistance precursor strains in Streptococcus pneumoniae from patients with community-acquired pneumonia despite high fluoroquinolone usage. Int J Med Microbiol: 2011; 301 1 53 57
39. Lismond A, Carbonnelle S, Tulkens PM, Van Bambeke F. Efflux of novel quinolones in contemporary Streptococcus pneumoniae isolates from community-acquired pneumonia. J Antimicrob Chemother: 2011; 66 4 948 951
40. Fuller JD, Low DE. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance. Clin Infect Dis: 2005; 41 1 118 121 (Pubitemid 40863754)
41. Arnold FW, Summersgill JT, Lajoie AS., et al. Community-Acquired Pneumonia Organization (CAPO) Investigators. A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med: 2007; 175 10 1086 1093 (Pubitemid 46741761)
42. Isozumi R, Yoshimine H, Morozumi M, Ubukata K, Ariyoshi K. Adult community-acquired pneumonia caused by macrolide resistant Mycoplasma pneumoniae. Respirology: 2009; 14 8 1206 1208
43. Morozumi M, Takahashi T, Ubukata K. Macrolide-resistant Mycoplasma pneumoniae: characteristics of isolates and clinical aspects of community-acquired pneumonia. J Infect Chemother: 2010; 16 2 78 86
44. Miyashita N, Maruyama T, Kobayashi T., et al. Community-acquired macrolide-resistant Mycoplasma pneumoniae pneumonia in patients more than 18 years of age. J Infect Chemother: 2011; 17 1 114 118
45. Bébéar C, Pereyre S, Peuchant O. Mycoplasma pneumoniae: susceptibility and resistance to antibiotics. Future Microbiol: 2011; 6 4 423 431
46. Hoban D, Felmingham D. The PROTEKT surveillance study: antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections. J Antimicrob Chemother: 2002; 50 Suppl S1 49 59
47. Tristram S, Jacobs MR, Appelbaum PC. Antimicrobial resistance in Haemophilus influenzae. Clin Microbiol Rev: 2007; 20 2 368 389 (Pubitemid 46709308)
48. McGregor K, Chang BJ, Mee BJ, Riley TV. Moraxella catarrhalis: clinical significance, antimicrobial susceptibility and BRO beta-lactamases. Eur J Clin Microbiol Infect Dis: 1998; 17 4 219 234 (Pubitemid 28356485)
49. Murphy TF, Parameswaran GI. Moraxella catarrhalis, a human respiratory tract pathogen. Clin Infect Dis: 2009; 49 1 124 131
50. Stefani S, Bongiorno D, Cafiso V., et al. Pathotype and susceptibility profile of a community-acquired methicillin-resistant Staphylococcus aureus strain responsible for a case of severe pneumonia. Diagn Microbiol Infect Dis: 2009; 63 1 100 104
51. Cataldo MA, Taglietti F, Petrosillo N. Methicillin-resistant Staphylococcus aureus: a community health threat. Postgrad Med: 2010; 122 6 16 23
52. Hidron AI, Low CE, Honig EG, Blumberg HM. Emergence of community-acquired methicillin-resistant Staphylococcus aureus strain USA300 as a cause of necrotising community-onset pneumonia. Lancet Infect Dis: 2009; 9 6 384 392
53. David MZ, Daum RS. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev: 2010; 23 3 616 687
54. Lobo LJ, Reed KD, Wunderink RG. Expanded clinical presentation of community-acquired methicillin-resistant Staphylococcus aureus pneumonia. Chest: 2010; 138 1 130 136
55. Marques MR, Nunes A, Sousa C, Moura F, Gouveia J, Ramos A. Community-acquired pneumonia in an intensive care unit. Rev Port Pneumol: 2010; 16 2 223 235
56. Sader HS, Sampaio JL, Zoccoli C, Jones RN. Results of the 1997 SENTRY Antimicrobial surveillance program in three Brazilian medical centres. Braz J Infect Dis: 1999; 3 2 63 79
57. Einhorn AE, Neuhauser MM, Bearden DT, Quinn JP, Pendland SL. Extended-spectrum beta-lactamases: frequency, risk factors, and outcomes. Pharmacotherapy: 2002; 22 1 14 20 (Pubitemid 34042384)
58. Kang C-I, Song J-H, Chung DR., et al. Korean Network for Study of Infectious Diseases (KONSID). Risk factors and treatment outcomes of community-onset bacteraemia caused by extended-spectrum β-lactamase- producing Escherichia coli. Int J Antimicrob Agents: 2010; 36 3 284 287
59. Tsai SS, Huang JC, Chen ST., et al. Characteristics of Klebsiella pneumoniae bacteremia in community-acquired and nosocomial infections in diabetic patients. Chang Gung Med J: 2010; 33 5 532 539
60. Teng CP, Chen HH, Chan J, Lye DCB. Ertapenem for the treatment of extended-spectrum β-lactamase-producing Gram-negative bacterial infections. Int J Antimicrob Agents: 2007; 30 4 356 359 (Pubitemid 47361714)
61. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science: 1999; 284 5418 1318 1322 (Pubitemid 29289651)
62. Hall-Stoodley L, Stoodley P. Evolving concepts in biofilm infections. Cell Microbiol: 2009; 11 7 1034 1043
63. Ojha AK, Baughn AD, Sambandan D., et al. Growth of Mycobacterium tuberculosis biofilms containing free mycolic acids and harbouring drug-tolerant bacteria. Mol Microbiol: 2008; 69 1 164 174 (Pubitemid 351832764)
64. Williams DW, Kuriyama T, Silva S, Malic S, Lewis MAO. Candida biofilms and oral candidosis: treatment and prevention. Periodontol 2000: 2011; 55 1 250 265
65. Deep A, Chaudhary U, Gupta V. Quorum sensing and bacterial pathogenicity: From molecules to disease. J Lab Physicians: 2011; 3 1 4 11
66. Nguyen KT, Piastro K, Gray TA, Derbyshire KM. Mycobacterial biofilms facilitate horizontal DNA transfer between strains of Mycobacterium smegmatis. J Bacteriol: 2010; 192 19 5134 5142
67. Anderson R, Feldman C. Key virulence factors of Streptococcus pneumoniae and non-typeable Haemophilus influenzae: roles in host defence and immunization. SA J Epidemiol Infect: 2011; 26 6 12
68. Federle MJ, Bassler BL. Interspecies communication in bacteria. J Clin Invest: 2003; 112 9 1291 1299 (Pubitemid 38057680)
69. Yang L, Liu Y, Wu H, Hóiby N, Molin S, Song ZJ. Current understanding of multi-species biofilms. Int J Oral Sci: 2011; 3 2 74 81
70. Elliott D, Burns JL, Hoffman LR. Exploratory study of the prevalence and clinical significance of tobramycin-mediated biofilm induction in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother: 2010; 54 7 3024 3026
71. Mathee K, Ciofu O, Sternberg C., et al. Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung. Microbiology: 1999; 145 Pt 6 1349 1357 (Pubitemid 29294920)
72. McInnis CE, Blackwell HE. Thiolactone modulators of quorum sensing revealed through library design and screening. Bioorg Med Chem: 2011; 19 16 4820 4828
73. Eberhard A, Burlingame AL, Eberhard C, Kenyon GL, Nealson KH, Oppenheimer NJ. Structural identification of autoinducer of Photobacterium fischeri luciferase. Biochemistry: 1981; 20 9 2444 2449
74. Fuqua C, Greenberg EP. Listening in on bacteria: acyl-homoserine lactone signalling. Nat Rev Mol Cell Biol: 2002; 3 9 685 695 (Pubitemid 34987789)
75. Galloway WRJD, Hodgkinson JT, Bowden SD, Welch M, Spring DR. Quorum sensing in Gram-negative bacteria: small-molecule modulation of AHL and AI-2 quorum sensing pathways. Chem Rev: 2011; 111 1 28 67
76. Zeng L-R, Xie J-P. Molecular basis underlying LuxR family transcription factors and function diversity and implications for novel antibiotic drug targets. J Cell Biochem: 2011; 112 11 3079 3084 10.1002/jcb.23262
77. Patankar AV, González JE. Orphan LuxR regulators of quorum sensing. FEMS Microbiol Rev: 2009; 33 4 739 756
78. Senadheera D, Cvitkovitch DG. Quorum sensing and biofilm formation by Streptococcus mutans. Adv Exp Med Biol: 2008; 631 178 188
79. Brackman G, Cos P, Maes L, Nelis HJ, Coenye T. Quorum sensing inhibitors increase the susceptibility of bacterial biofilms to antibiotics in vitro and in vivo. Antimicrob Agents Chemother: 2011; 55 6 2655 2661
80. Ng WL, Bassler BL. Bacterial quorum-sensing network architectures. Annu Rev Genet: 2009; 43 197 222
81. Xavier KB, Bassler BL. Interference with AI-2-mediated bacterial cell-cell communication. Nature: 2005; 437 7059 750 753 (Pubitemid 41486545)
82. Neiditch MB, Federle MJ, Miller ST, Bassler BL, Hughson FM. Regulation of LuxPQ receptor activity by the quorum-sensing signal autoinducer-2. Mol Cell: 2005; 18 5 507 518 (Pubitemid 40726228)
83. Yoshida A, Ansai T, Takehara T, Kuramitsu HK. LuxS-based signaling affects Streptococcus mutans biofilm formation. Appl Environ Microbiol: 2005; 71 5 2372 2380 (Pubitemid 40646979)
84. Vidal JE, Ludewick HP, Kunkel RM, Zähner D, Klugman KP. The LuxS-dependent quorum-sensing system regulates early biofilm formation by Streptococcus pneumoniae strain D39. Infect Immun: 2011; 79 10 4050 4060
85. Armbruster CE, Swords WE. Interspecies bacterial communication as a target for therapy in otitis media. Expert Rev Anti Infect Ther: 2010; 8 10 1067 1070
86. Cloak OM, Solow BT, Briggs CE, Chen C-Y, Fratamico PM. Quorum sensing and production of autoinducer-2 in Campylobacter spp., Escherichia coli O157:H7, and Salmonella enterica serovar Typhimurium in foods. Appl Environ Microbiol: 2002; 68 9 4666 4671 (Pubitemid 34988156)
87. Anderson GG, O'Toole GA. Innate and induced resistance mechanisms of bacterial biofilms. Curr Top Microbiol Immunol: 2008; 322 85 105
88. Hoiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O. Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents: 2010; 35 4 322 332
89. Roberts AP, Mullany P. Oral biofilms: a reservoir of transferable, bacterial, antimicrobial resistance. Expert Rev Anti Infect Ther: 2010; 8 12 1441 1450
90. Antonova ES, Hammer BK. Quorum-sensing autoinducer molecules produced by members of a multispecies biofilm promote horizontal gene transfer to Vibrio cholerae. FEMS Microbiol Lett: 2011; 322 1 68 76
91. Król JE, Nguyen HD, Rogers LM, Beyenal H, Krone SM, Top EM. Increased transfer of a multidrug resistance plasmid in Escherichia coli biofilms at the air-liquid interface. Appl Environ Microbiol: 2011; 77 15 5079 5088
92. Vaidya VK. Horizontal transfer of antimicrobial resistance by extended spectrum β-lactamase-producing Enterobacteriaceae. J Lab Physicians: 2011; 3 1 37 42
93. Budhani RK, Struthers JK. Interaction of Streptococcus pneumoniae and Moraxella catarrhalis: investigation of the indirect pathogenic role of beta-lactamase-producing moraxellae by use of a continuous-culture biofilm system. Antimicrob Agents Chemother: 1998; 42 10 2521 2526 (Pubitemid 28462888)
94. Weimer KE, Juneau RA, Murrah KA., et al. Divergent mechanisms for passive pneumococcal resistance to β-lactam antibiotics in the presence of Haemophilus influenzae. J Infect Dis: 2011; 203 4 549 555
95. Miyahara E, Nishie M, Takumi S., et al. Environmental mutagens may be implicated in the emergence of drug-resistant microorganisms. FEMS Microbiol Lett: 2011; 317 2 109 116
96. Bagaitkar J, Demuth DR, Daep CA, Renaud DE, Pierce DL, Scott DA. Tobacco upregulates P. gingivalis fimbrial proteins which induce TLR2 hyposensitivity. PLoS ONE: 2010; 5 5 e9323
97. Goldstein-Daruech N, Cope EK, Zhao K-Q., et al. Tobacco smoke mediated induction of sinonasal microbial biofilms. PLoS ONE: 2011; 6 1 e15700
98. Ginaldi L, Loreto MF, Corsi MP, Modesti M, De Martinis M. Immunosenescence and infectious diseases. Microbes Infect: 2001; 3 10 851 857 (Pubitemid 32913168)
99. McElhaney JE, Effros RB. Immunosenescence: what does it mean to health outcomes in older adults? Curr Opin Immunol: 2009; 21 4 418 424
100. Yoshikawa TT. Antimicrobial resistance and aging: beginning of the end of the antibiotic era? J Am Geriatr Soc: 2002; 50 7, Suppl S226 S229 (Pubitemid 34811965)
101. Girard TD, Opal SM, Ely EW. Insights into severe sepsis in older patients: from epidemiology to evidence-based management. Clin Infect Dis: 2005; 40 5 719 727 (Pubitemid 40381348)
102. Tachfouti N, Nejjari C, Benjelloun MC., et al. Association between smoking status, other factors and tuberculosis treatment failure in Morocco. Int J Tuberc Lung Dis: 2011; 15 6 838 843
103. Nuorti JP, Butler JC, Farley MM., et al. Active Bacterial Core Surveillance Team. Cigarette smoking and invasive pneumococcal disease. N Engl J Med: 2000; 342 10 681 689 (Pubitemid 30131420)
104. Stanley PJ, Wilson R, Greenstone MA, MacWilliam L, Cole PJ. Effect of cigarette smoking on nasal mucociliary clearance and ciliary beat frequency. Thorax: 1986; 41 7 519 523 (Pubitemid 16070385)
105. Manzel LJ, Shi L, O'Shaughnessy PT, Thorne PS, Look DC. Inhibition by cigarette smoke of nuclear factor-κB-dependent response to bacteria in the airway. Am J Respir Cell Mol Biol: 2011; 44 2 155 165
106. Kulkarni R, Rampersaud R, Aguilar JL, Randis TM, Kreindler JL, Ratner AJ. Cigarette smoke inhibits airway epithelial cell innate immune responses to bacteria. Infect Immun: 2010; 78 5 2146 2152
107. Phipps JC, Aronoff DM, Curtis JL, Goel D, O'Brien E, Mancuso P. Cigarette smoke exposure impairs pulmonary bacterial clearance and alveolar macrophage complement-mediated phagocytosis of Streptococcus pneumoniae. Infect Immun: 2010; 78 3 1214 1220
108. Feng Y, Kong Y, Barnes PF., et al. Exposure to cigarette smoke inhibits the pulmonary T-cell response to influenza virus and Mycobacterium tuberculosis. Infect Immun: 2011; 79 1 229 237
109. Zhang Y. Mechanisms of antibiotic resistance in the microbial world. www.moleculartb.org/gb/pdf/transcriptions/11-YZHANG.pdf
110. Lönn-Stensrud J, Landin MA, Benneche T, Petersen FC, Scheie AA. Furanones, potential agents for preventing Staphylococcus epidermidis biofilm infections? J Antimicrob Chemother: 2009; 63 2 309 316
111. Brackman G, Celen S, Hillaert U., et al. Structure-activity relationship of cinnamaldehyde analogs as inhibitors of AI-2 based quorum sensing and their effect on virulence of Vibrio spp. PLoS ONE: 2011; 6 1 e16084
112. Bunders CA, Richards JJ, Melander C. Identification of aryl 2-aminoimidazoles as biofilm inhibitors in gram-negative bacteria. Bioorg Med Chem Lett: 2010; 20 12 3797 3800
113. Steenackers HP, Ermolat'ev DS, Savaliya B., et al. Structure-activity relationship of 2-hydroxy-2-aryl-2,3-dihydro-imidazo[1,2-a]pyrimidinium salts and 2N-substituted 4(5)-aryl-2-amino-1H-imidazoles as inhibitors of biofilm formation by Salmonella typhimurium and Pseudomonas aeruginosa. Bioorg Med Chem: 2011; 19 11 3462 3473
114. Budzyska A, Rózalski M, Karolczak W, Wieckowska-Szakiel M, Sadowska B, Rózalska B. Synthetic 3-arylideneflavanones as inhibitors of the initial stages of biofilm formation by Staphylococcus aureus and Enterococcus faecalis. Z Naturforsch C: 2011; 66 3-4 104 114
115. Bunders C, Cavanagh J, Melander C. Flustramine inspired synthesis and biological evaluation of pyrroloindoline triazole amides as novel inhibitors of bacterial biofilms. Org Biomol Chem: 2011; 9 15 5476 5481
116. Sintim HO, Smith JAJ, Wang J, Nakayama S, Yan L. Paradigm shift in discovering next-generation anti-infective agents: targeting quorum sensing, c-di-GMP signaling and biofilm formation in bacteria with small molecules. Future Med Chem: 2010; 2 6 1005 1035
117. Kirchdoerfer RN, Garner AL, Flack CE., et al. Structural basis for ligand recognition and discrimination of a quorum-quenching antibody. J Biol Chem: 2011; 286 19 17351 17358
118. Chaignon P, Sadovskaya I, Ragunah Ch, Ramasubbu N, Kaplan JB, Jabbouri S. Susceptibility of staphylococcal biofilms to enzymatic treatments depends on their chemical composition. Appl Microbiol Biotechnol: 2007; 75 1 125 132 (Pubitemid 46669217)
119. Hoiby N, Ciofu O, Johansen HK., et al. The clinical impact of bacterial biofilms. Int J Oral Sci: 2011; 3 2 55 65
120. Stables MJ, Newson J, Ayoub SS, Brown J, Hyams CJ, Gilroy DW. Priming innate immune responses to infection by cyclooxygenase inhibition kills antibiotic-susceptible and -resistant bacteria. Blood: 2010; 116 16 2950 2959
121. O'Neill LAJ, Bryant CE, Doyle SL. Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol Rev: 2009; 61 2 177 197
122. Nicholls EF, Madera L, Hancock REW. Immunomodulators as adjuvants for vaccines and antimicrobial therapy. Ann N Y Acad Sci: 2010; 1213 46 61
123. Serezani CH, Ballinger MN, Aronoff DM, Peters-Golden M. Cyclic AMP: master regulator of innate immune cell function. Am J Respir Cell Mol Biol: 2008; 39 2 127 132